A straightforward quantitative method for gas chromatography-mass spectrometry determination of isosorbide 5-mononitrate (ISSMN) and its related impurities such as isosorbide (IS), isosorbide diacetate (ISDA) and isosorbide 2-acetate-5-nitrate (IS2A5N) in raw materials as well as in dosage formulations is developed. The recovery of these materials was found to be 100.4 +/- 2.4, 99.3 +/- 4.7, 97.8 +/- 5.2 and 100.1 +/- 3.1%, while the detection limits were 27.2, 1.26, 1.02 and 0.78 mu g in dosage formulations for ISSMN, ISDA, IS2A5N, and IS, respectively. The applicability of the method was tested by analysing three different formulations of ISSMN.
Source:
Journal of Pharmaceutical and Biomedical Analysis, 1997, 16, 3, 425-429
TY - JOUR
AU - Marinković, Valentina
AU - Milojković, SS
AU - Nedeljković, Jovan M.
AU - Comor, JJ
AU - Agbaba, Danica
AU - Živanov-Stakić, Dobrila
PY - 1997
UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/153
AB - A straightforward quantitative method for gas chromatography-mass spectrometry determination of isosorbide 5-mononitrate (ISSMN) and its related impurities such as isosorbide (IS), isosorbide diacetate (ISDA) and isosorbide 2-acetate-5-nitrate (IS2A5N) in raw materials as well as in dosage formulations is developed. The recovery of these materials was found to be 100.4 +/- 2.4, 99.3 +/- 4.7, 97.8 +/- 5.2 and 100.1 +/- 3.1%, while the detection limits were 27.2, 1.26, 1.02 and 0.78 mu g in dosage formulations for ISSMN, ISDA, IS2A5N, and IS, respectively. The applicability of the method was tested by analysing three different formulations of ISSMN.
PB - Pergamon-Elsevier Science Ltd, Oxford
T2 - Journal of Pharmaceutical and Biomedical Analysis
T1 - Gas chromatography mass spectrometry determination of isosorbide 5-mononitrate and related impurities in raw materials and dosage formulations
VL - 16
IS - 3
SP - 425
EP - 429
DO - 10.1016/S0731-7085(97)00079-4
ER -
@article{
author = "Marinković, Valentina and Milojković, SS and Nedeljković, Jovan M. and Comor, JJ and Agbaba, Danica and Živanov-Stakić, Dobrila",
year = "1997",
abstract = "A straightforward quantitative method for gas chromatography-mass spectrometry determination of isosorbide 5-mononitrate (ISSMN) and its related impurities such as isosorbide (IS), isosorbide diacetate (ISDA) and isosorbide 2-acetate-5-nitrate (IS2A5N) in raw materials as well as in dosage formulations is developed. The recovery of these materials was found to be 100.4 +/- 2.4, 99.3 +/- 4.7, 97.8 +/- 5.2 and 100.1 +/- 3.1%, while the detection limits were 27.2, 1.26, 1.02 and 0.78 mu g in dosage formulations for ISSMN, ISDA, IS2A5N, and IS, respectively. The applicability of the method was tested by analysing three different formulations of ISSMN.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
title = "Gas chromatography mass spectrometry determination of isosorbide 5-mononitrate and related impurities in raw materials and dosage formulations",
volume = "16",
number = "3",
pages = "425-429",
doi = "10.1016/S0731-7085(97)00079-4"
}
Marinković, V., Milojković, S., Nedeljković, J. M., Comor, J., Agbaba, D.,& Živanov-Stakić, D.. (1997). Gas chromatography mass spectrometry determination of isosorbide 5-mononitrate and related impurities in raw materials and dosage formulations. in Journal of Pharmaceutical and Biomedical Analysis
Pergamon-Elsevier Science Ltd, Oxford., 16(3), 425-429.
https://doi.org/10.1016/S0731-7085(97)00079-4
Marinković V, Milojković S, Nedeljković JM, Comor J, Agbaba D, Živanov-Stakić D. Gas chromatography mass spectrometry determination of isosorbide 5-mononitrate and related impurities in raw materials and dosage formulations. in Journal of Pharmaceutical and Biomedical Analysis. 1997;16(3):425-429.
doi:10.1016/S0731-7085(97)00079-4 .
Marinković, Valentina, Milojković, SS, Nedeljković, Jovan M., Comor, JJ, Agbaba, Danica, Živanov-Stakić, Dobrila, "Gas chromatography mass spectrometry determination of isosorbide 5-mononitrate and related impurities in raw materials and dosage formulations" in Journal of Pharmaceutical and Biomedical Analysis, 16, no. 3 (1997):425-429,
https://doi.org/10.1016/S0731-7085(97)00079-4 . .
